이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

FibroGen 관리

관리 기준 확인 2/4

FibroGen's CEO는 Thane Wettig, Jul2023 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 3.64M, 15.7% 로 구성됩니다. 15.7% 급여 및 84.3% 보너스(회사 주식 및 옵션 포함). 는 $ 195.14K 가치에 해당하는 회사 주식의 0.19% 직접 소유합니다. 195.14K. 경영진과 이사회의 평균 재임 기간은 각각 2.9 년과 5.3 년입니다.

주요 정보

Thane Wettig

최고 경영자

US$3.6m

총 보상

CEO 급여 비율	15.7%
CEO 임기	less than a year
CEO 소유권	0.2%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	5.3yrs

최근 관리 업데이트

Recent updates

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

Jul 04

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

FibroGen Q2 2022 Earnings Preview

Aug 05

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Jul 06

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Mar 31

Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Mar 05

Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

Dec 08

News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are Under Threat

Aug 12

Downgrade: Here's How Analysts See FibroGen, Inc. (NASDAQ:FGEN) Performing In The Near Term

Jul 17

CEO 보상 분석

Thane Wettig 의 보수는 FibroGen 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$240m
Dec 31 2023	US$4m	US$573k	-US$284m
Sep 30 2023	n/a	n/a	-US$294m
Jun 30 2023	n/a	n/a	-US$322m
Mar 31 2023	n/a	n/a	-US$307m
Dec 31 2022	US$3m	US$535k	-US$294m
Sep 30 2022	n/a	n/a	-US$362m
Jun 30 2022	n/a	n/a	-US$220m
Mar 31 2022	n/a	n/a	-US$281m
Dec 31 2021	US$3m	US$510k	-US$290m
Sep 30 2021	n/a	n/a	-US$215m
Jun 30 2021	n/a	n/a	-US$231m
Mar 31 2021	n/a	n/a	-US$183m
Dec 31 2020	US$4m	US$263k	-US$189m

보상 대 시장: Thane 의 총 보상 ($USD 3.64M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Thane 의 보상이 증가했습니다.

CEO

Thane Wettig (59 yo)

less than a year

테뉴어

US$3,640,829

보상

Mr. Thane Wettig serves as Director of FibroGen, Inc. since October 2, 2023. He serves as Chief Executive Officer at FibroGen, Inc. since October 2, 2023 and served as Interim Chief Executive Officer since...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thane Wettig	CEO & Director	less than a year	US$3.64m	0.19% $ 131.7k
Juan Graham	Senior VP & CFO	2.8yrs	US$3.09m	0.065% $ 44.6k
Christine Chung	Senior Vice President of China Operations	17.5yrs	US$3.11m	0.32% $ 222.3k
Barry Berkowitz	Founder	29.5yrs	데이터 없음	데이터 없음
John Hunter	Chief Scientific Officer	3yrs	데이터 없음	데이터 없음
David DeLucia	Vice President of Corporate FP&A and Investor Relations	no data	데이터 없음	데이터 없음
Michael Lowenstein	Chief Legal Officer	8.3yrs	데이터 없음	데이터 없음
Tricia Stewart	Chief People Officer	3.2yrs	데이터 없음	데이터 없음
Kirk Christoffersen	Chief Business Officer	3.7yrs	데이터 없음	데이터 없음
Rahul Kaushik	Senior Vice President of Pharmaceutical Development	2.5yrs	데이터 없음	데이터 없음
Elizabeth Bearby	Senior VP of Regulatory	less than a year	데이터 없음	데이터 없음
Deyaa Adib	Senior VP & Chief Medical Officer	less than a year	데이터 없음	0.083% $ 56.7k

3.0yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: FGEN 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thane Wettig	CEO & Director	less than a year	US$3.64m	0.19% $ 131.7k
George Martin	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Suzanne Blaug	Independent Director	5.1yrs	US$388.03k	0.021% $ 14.7k
Jeffrey Edwards	Independent Director	8.8yrs	US$385.53k	0.026% $ 17.7k
James Schoeneck	Independent Chairman of the Board	14.3yrs	US$499.58k	0.082% $ 56.3k
Gerald Lema	Independent Director	6.8yrs	US$383.03k	0.037% $ 25.6k
Maykin Ho	Independent Director	5.6yrs	US$375.53k	0.023% $ 16.0k
Benjamin Cravatt	Independent Director	3.9yrs	US$392.55k	0.021% $ 14.1k
Aoife Brennan	Independent Director	3.9yrs	US$373.03k	0.020% $ 13.6k

5.3yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: FGEN 의 이사회는 경험(평균 재직 기간 5.3 년)으로 간주됩니다.

FibroGen 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

CEO & Director recently bought US$95k worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Chief Executive Officer Changes

Recent updates

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Index

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

CEO & Director recently bought US$95k worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings: EPS and revenues miss analyst expectations

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

New major risk - Financial position

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Now 25% undervalued after recent price drop

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Now 30% undervalued after recent price drop

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 17% to US$10.38

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fibrogen, Inc. Announces Chief Executive Officer Changes

FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 25% to US$19.00

Now 81% undervalued after recent price drop

Insider notifies of intention to sell stock

FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Insider recently sold US$124k worth of stock

CEO & Director recently sold US$1.2m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 16% to US$24.83

FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Price target increased by 21% to US$21.33

Price target increased to US$17.60

Chief Financial Officer notifies of intention to sell stock

Now 20% undervalued

Price target increased to US$16.40

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Price target increased to US$16.40

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

FibroGen, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Consensus forecasts updated

Price target increased to US$14.40

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

FibroGen Q2 2022 Earnings Preview